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ABSTRACT
Purpose: To compare increment of bone mineral density (BMD) with pamidronate, zoledronate and the isolated effect of proteinous 
diet in undernourished oophorectomized and non-oophorectomized female rats, besides validating BMD’s indexes. Methods: 60 young 
female Lewis rats were divided into five experimental groups and a control group, oophorectomized and non-oophorectomized. The 
administration of drugs were submitted to proteinous and aproteinous diets. The variables analyzed were weight, bone densitometry, 
histomorphometry and biochemical evolution. Results: In weight evaluation, the first interval showed a statistically meaningful increase 
in oophorectomized sample. In densitometry evaluation, the first interval showed statistically meaningful decrease in four medicated 
groups and third showed a statistically meaningful increase in 2 non-oophorectomized groups. In laboratory evaluation, there were an 
increase of total proteins and globulin, decrease of alkaline phosphatase, phosphorus and calcium (except for the oophorectomized) 
in four medicated groups and increase of phosphorus and calcium in 2 not medicated groups. In histomorphometric evaluation, the 
oophorectomized groups had smaller increment of BMD. Conclusions: The pamidronate and zoledronate have shown effectives in the 
increment of BMD. The proteinous diet itself possesses therapeutic effect in BMD though not significant compared with medicated 
animals. The results of histomorphometry allow validating BMD’s indexes in this experimental model.
Key words: Osteoporosis. Bone Density. Densitometry. Ovariectomy, Diphosphonates. Rats.
RESUMO
Objetivo: Comparar o incremento de densidade mineral óssea (DMA) com pamidronato, zoledronato e o efeito isolado de dieta protéica 
em ratas desnutridas ooforectomizadas e não ooforectomizadas, além de validar índices de DMA. Métodos: 60 ratas jovens Lewis foram 
divididas em cinco grupos experimentais e um grupo controle, com e sem ooforectomia. A administração das drogas foi submetida 
às dietas protéica e aprotéica. As variáveis analisadas foram peso, densitometria óssea, histomorfometria e evolução bioquímica. 
Resultados: Na avaliação ponderal, o primeiro intervalo mostrou aumento estatisticamente significante nos grupos ooforectomizados. 
Na avaliação densitométrica, o primeiro intervalo mostrou diminuição estatisticamente significante nos quatro grupos medicados e 
o terceiro mostrou aumento estatisticamente significante nos dois não ooforectomizados. Na avaliação laboratorial, houve aumento 
de proteínas totais e globulina, diminuição de fosfatase alcalina, fósforo e cálcio (exceto nos ooforectomizados) nos quatro grupos 
medicados e aumento de fósforo e cálcio nos dois não medicados. Na avaliação histomorfométrica, os grupos ooforectomizados tiveram 
incremento menor de DMA. Conclusões: O pamidronato e o zoledronato se mostraram efetivos no incremento de DMA. A dieta 
protéica em si possui efeito terapêutico na DMA, porém menos significativa, comparada aos animais medicados. Os resultados da 
histomorfometria permitem validar os índices de DMA neste modelo experimental.
Descritores: Osteoporose. Densidade Óssea. Densitometria. Ovariectomia. Difosfonatos. Ratos. 
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Introduction
As number and gravity of spine and femoral fractures 
increase, mainly caused by osteoporosis, it has been noted the 
need for an efficient and        short-term treatment. These fractures 
cause huge social and economical damages to individuals who 
have less work capability, the elderly, stricken by this disease. 
Another important aspect is that these individuals usually need 
longer recovery time. 
Due to the seriousness of the issue, the SBOT – Brazilian 
Society of Orthopedics and Traumatology has been broadcast a 
national campaign for preventing osteoporosis since 1998.
New drugs for osteoporosis treatment are being tested, 
many of them developed in various research centers worldwide1,2. 
The progress in the treatment of osteoporosis is supported by 
an improvement in medicine treatment that takes place with the 
findings of drugs that promote bone resorption decrease. 
Sodium fluoride is one of the available agents for 
osteoporosis treatment that stimulates bone tissue formation. 
Other medicines, such as pamidronate, zoledronate, residronate 
and alendronate act by reducing bone resorption.
The pamidronate and zoledronate effects in reducing 
bone resorption level are an issue one should focus on 
intravenous pamidronate and zoledronate capacity to act by 
decreasing bone resorption with and without the aggravation of 
proteinous malnourishment is the issue that will be evaluated and 
measured by experiment through criteria of weight, densitometry, 
biochemistry and histomorphometry3,4.
The objectives of this study are to evaluate pamidronate 
and zoledronate effects in the increase of bone mineral density 
in malnourished oophorectomized and non–oophorectomized 
female rats. Beyond this, to evaluate the isolated effect 
of proteinous diet on bone mineral density’s increment in 
malnourished female rats, and validate bone mineral density 
indexes obtained by bone densitometry at the end of the treatment 
with pamidronate, zoledronate and proteinous diet by analysis of 
bone histomorphometry in different groups of animals studied. 
Methods
Female Lewis rats, albines, in a total of sixty young 
(ages under 120 days) healthy, initially weighting between 
140-260g, were raised at the Central Animal colony in Parana 
University Hospital, belonging Londrina State University.
These animals were initially divided into six groups 
(control group and A, B, C, D and E experimental groups), each 
one with ten animals, divided into 12 cages with five animals 
each. Cages were made of opaque polyethylene and closed 
with stainless steel lid, as a grid, covered with wood shavings, 
changed twice a week. The light period was twelve hours with 
stable temperature, humidity and noise levels. Ten animals (from 
control group) were given standardized food (balanced diet for 
rats) and ad libitium distilled water. The other fifty animals 
(experimental groups) underwent aproteinous diet and ad libitum 
distilled water. The animals were numbered from 1 to 60 on its 
ears, according to the laboratory animal’s patterning.
Cages were identified into 2 groups: the ones of the 
experimental groups A, B, C, D and E which received aproteinous 
diet for 3 weeks (components described below); and the ones of 
the control group which received balanced diet for rats and include 
pamidronate and zoledronate. Components of aproteinous diet1: 
MgSO4 (94,5g); NaCl (240g); KCl (120g); FeSO4 (NH4)2 SO4, 
6H2O (21,6g); CaSO4 ou CaCl2 (1,2g); MnSO4 (1,2g); ZnSC4 
(1,5g); K (0,063g); CaHSO4 (720g); benzoic acid (30g) and corn 
starch q. s. p. (30.000g). 
Study’s exclusion criteria were animals with any type of 
disease, besides restriction of food other than established diets; it 
was mainly rejected the administration of other drugs and liquids 
different from those of the experiment. This total experimental 
period was 89 days.
The animals were randomly divided into groups, where 
weight, and densitometric, biochemical and histomorphometric 
criteria were evaluated, measured and compared:
- Control group: comprised 10 animals that received a normal 
lab diet along the whole study, and were after evaluated 
according to this study parameters;
- Experimental group A: comprised 10 oophorectomized 
animals that received aproteinous diet along three weeks, 
and by the end they received pamidronate medication, in 
dose of 1 mg/kg (weight) and were after evaluated according 
to this study parameters.
- Experimental group B: comprised 10 oophorectomized 
animals that received aproteinous diet along three weeks 
and by the end, they were given zoledronate in dose of 0.04 
mg/kg and were later evaluated by these study parameters.
- Experimental group C: comprised 10 animals that received 
aproteinous diet along three weeks, and by the end were 
given zoledronate, in dose of 0.04 mg / kg and were later 
evaluated by these study parameters. 
- Experimental group D: comprised 10 animals, that received 
aproteinous diet during three weeks, and after were given 
pamidronate, in dose of 1 mg/ kg, later assessed by this 
study parameters;
- Experimental group E: comprised 10 animals, that received 
aproteinous diet during three weeks, without medication 
administration, and were later evaluated by these study 
parameters. 
Oophorectomy and drugs administration criteria 
The animals were anesthetized for oophorectomy. 
Anesthesia was intraperitoneally injected, after inhalatory 
sulfuric ether sedation. It was used a mixture of ketamine, an 
anesthetic drug, and myorelaxant xilazine in proportion of 1:1.
Bone densitometry was carried out only after sedation 
with inhalatory sulfuric acid during 1 minute. Oophorectomy 
was performed bilaterally, with the animal on decubitus and by 
central incision. Only one rat from the pamidronate group died 
of inflammatory complications. 
Pamidronate and zoledronate were provided by a 
pharmaceutical laboratory. After this, it was prepared for 
administration on animals at the Bioterium of the Post Graduation 
Laboratory at College of Medicine in Londrina State University. 
Doses dilutions were 1 mg/kg of pamidronate and 0.04 mg/ kg 
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of zoledronate. The administration of the first dose was given 
shortly after the end of aproteinous diet (21 days), and the second 
dose occurred after each one’s biological half-life (pamidronate 
at 38 days and zoledronate at 55 days). 
Evaluation criteria and measurement methods
Study’s animals were evaluated according to weight 
evolution, densitometry, histomorphometry, albumin’s blood 
dosage, total proteins and globulin, and calcium, phosphorus and 
blood alkaline phosphatase of dosages. All animals were weighted 
three times: at the first day of the study, after pamidronate’s drug 
effect (eighth week) and after zoledronate’s drug effect (thirteenth 
week). Animals’ body weight’s evolution was checked through 
Helmac HM 5000® electronic balance, by grams.
All animals femoral bone mineral density measured 
by a LUNAR densitometer (DPX ALFA), set at a private clinic, 
the Clinilab Imagem. It was used a software in a high resolution 
mode for small animals. 
Bone mineral densities of right femoral shafts were 
measured in       grams per cm2. Demarcation was performed by 
delimited areas (ROIs) and quantified by specific software. After 
processing, the graphics were analyzed in order to compare bone 
mineral density’s values between various medicated groups and 
control group.
Histomorphometrical evaluations were performed 
using an image analysis system (Kontron Electronic 300). The 
workstation consisted of a Zeiss ifferent light microscope, 
a colored video camera (Sony CCD – Iris), images scanner, a 
microcomputer with Pentium processor 133MHz, IBM-PC 
compatible, operating in Windows 95-32 bits.
Images were digitalized through a specific software for 
image analysis (Kontron Electronic 300), allowing data recording 
with text processor      (Microsoft Word) and in an electronic 
worksheet (Microsoft Excel). By using these softwares, it was 
possible to set the analysis treatment, interpretation, measurement 
values of the structures, with all the variables and data automatic 
distribution, generated by the images workstation analyzer for 
electronic worksheets and text processors, automatically.
Images calibration was performed amplified four times. 
This quantification was set at the smallest special unit, the pixel. 
Calibration factor (CF) was automatically calculated in pixels and 
as such it was used by the calculation program in micrometers, 
according with calibration. Images were assessed by Kontron 
300 (Zeiss), program which allowed area determination. This 
tool allowed to identify the structure mark and automatize its 
identification for future readings, like filters usage and appliance 
of multiple macros for various tasks’ automation.
Histological cuts were processed through image 
analyzing system, by using a 4x objective and 10x ocular. Images 
were captured by a video camera and digitalized by the computer’s 
special digitalization plaque, used for images optimization. After 
image delivery, it was used a graphical resource for making 
the structures to be quantified. By using the mouse, one has 
delimited bone area to be measured by square micrometer. All 
these measures were saved at computer’s specific program, for 
future statistical analysis.
Albumin, total proteins and globulin’s blood dosage was 
carried out at the Post Graduation Laboratory of the University 
Hospital at Londrina State University. It was proceeded in 
a SELECTRA automation machine. Albumin was dosed by 
bromocresol green method (BCG), and total proteins by a biuret 
method. Results were measured in grams by deciliter of blood 
and normal results are respectively: 3.40 – 5.00 g/dl and 6.40 – 
8.20 g/dl.
Globulin is the result of albumin’s total protein 
subtraction and the relationship between albumin and globulin’s 
division. Results were measured in grams by deciliter of blood 
and normal results are, respectively: 2.00–3.50 g/dl and     1.50–
2.50 g/dl. Among lab investigations of bone metabolism, it was 
performed the measurement of calcium seric concentrations, 
phosphorus and alkaline phosphatase. 
The process occurred in a SELECTRA automation 
machine.  Calcium was dosed by ortho-cresolphtalein (o-CPC) 
method and measured in milligram by deciliter; and phosphorus 
was dosed by ultraviolet molybdate method and measured 
in milligram / deciliter. For your turn, alkaline phosphatase 
by Bowers and McComb kinetic method and measured by 
international units per liter. Normal results are respectively: 8.50 
– 10.1 mg/dl, 2.50 – 4.90 mg/dl and        50 – 136 iu/l.
 Statistical analysis
Weight, densitometric, laboratory and histomorphometric 
variables were analyzed in order to establish the following 
comparisons: 1) Group A x control group; 2) Group B x control 
group; 3) Group C x control group;                           4) Group D 
x control group and 5) Group E x control group. For variable’s 
description, one used arithmetic mean and patter deviation 
shown in tables according to study’s medications. The hypothesis 
formulated at study’s planning was checked by repeated measures 
analysis of variance technique with a classification factor. 
Tests were performed in a 5% significance level which 
means that tests were considered meaningful when p < 0.05, and 
processed on software SAS (Statistical Analysis System). 
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Results
The three weight variables were achieved on the first day 
of study (weight 1), on the 55th day, after the effect of medications 
first doses (weight 2), and on the 89th day, after second doses of 
medications effect (weight 3), as shows Figure 1.                                        
 
FIGURE 1 – Comparison between pondered variables for groups A, B, 
C, D, E and control group.
The five densitometric variables were achieved on 
the first day of study (BMD 1); on the 21st day, after ending 
aproteinous diet (BMD 2); on the 38th day after 1st doses effect 
of pamidronate (BMD 3). In order of succession, on the 55th day, 
after 2nd doses effect of pamidronate and 1st zoledronate doses 
(BMD 4) and on the 89th day, after effect of zoledronate 2nd doses 
effect (BMD 5), as shows Figure 2.
118 - Acta Cirúrgica Brasileira - Vol. 26 (2) 2011
Barbieri A et al.
FIGURE 2 – Comparison between densitometric variables for groups 
A, B, C, D, E and control group
Results of experimental groups in comparison with 
control group for weight and densitometric variables are shown 
on Table 1. 
The two laboratorial variables were carried out at the 
beginning of medication use (21st day) and at the end of the 
response to medications used (89th day). Table 2 shows the 
results of albumin dosages, total proteins, globulins, relation 
albumin/globulin, alkaline phosphatase, phosphorus and calcium 
of experimental groups in comparison to the control group.
Histomorphometric variable was performed at the end 
of the whole study      (89th day). The areas were compared by 
using the Student’s T test, because the Test by Bartlett detected 
homogeneity of variances. Results showed no significant 
differences in all the comparisons made.  
Diet Pondered data Densitometric data
Weight 1-2 Weight 2-3 BMD 1-2 BMD 2-3 BMD 3-4 BMD 4-5
Group A 0,0103 0,1729 0,1302 0,0152 0,9519 -
Group B 0,0358 0,5837 0,0053 0,0003 - 0,9432
Group C 0,2409 0,2760 0,0001 0,2834 - 0,0131
Group D 0,2019 0,5423 0,0008 0,1869 0,0234 -
Group E 0,3402 0,7620 0,0649 0,5309 0,6503 0,1708
Diet Albumine
Total 
proteins
Globulins
Relation A/
G1
Alkaline 
Phosphatase 
Phosphorus Calcium
Group A 0,4926 0,0001 < 0,0001 0,0076 0,2607 < 0,0001 0,1136
Group B 0,4007 0,0109 0,0034 0,1323 0,1522 0,0002 0,3942
Group C 0,2694 0,0269 0,0093 0,8548 0,2118 0,0009 0,0015
Group D 0,5441 0,1577 0,0482 0,0947 0,2925 0,4387 0,0108
Group E 0,7538 0,5609 0,5311 0,9598 0,0616 0,7100 0,4135
A/G1 = albumine/globulin
TABLE 2 – Value of p of the variance analysis for measures repeated to evaluate the effect of intervention (experimental groups x 
control) in laboratorial exams
TABLE 1 – Value of p of the variance analysis for measures repeated to evaluate the effect of intervention (experimental groups x 
control) in the weight of rats and in the mass’ bone density
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Discussion 
In this experiment, the species under study was female 
rats under four months old, considered young adults, although 
they were still growing, it was considered a slow growth. 
Moreover, other researchers reported having used animals with a 
similar age in previous studies5. It is worth to highlight that the 
uniform general characteristics of all animals at the beginning 
of the study, which, in fact allowed a longitudinal and vertical 
groups analysis. Baron et al.6 showed that animals at this age 
present a degree of bone remodeling / transformation similar 
to an adult human. The studies of animals, which have a more 
stable bone development (from six months to one year old) are 
not so practical, due to the longer maintenance period of these 
animals. Moreover, bone transformations are slower.  
The time necessary to observe bone alterations after 
performing oophorectomy was around three weeks. Some authors 
did not need a period of more than four weeks7, whereas other 
researchers were able to observe that only after six months8. 
However, in the great majority of studies, the time needed was 
just a few weeks9. It is an interesting model, since it is known 
that bone transformations in human beings are slower and bone 
loss occurs throughout many years, which hinders or limits some 
clinical studies.  
The weight of the animals increased in all groups, as 
expected, since they were undergoing a growing phase. There was 
no significant difference among the groups, a fact that contrasts 
with the literature data that demonstrated higher weight gains 
in the oophorectomized animals10. This is a fact that minimizes 
bone loss but does not prevent it11. 
BMD analysis was carried out by densitometry, a 
technique has already been used in human beings for more than 
one decade. Such method is considered more practical and direct 
than other methods previously used, and it is broadly used for 
osteoporosis diagnosis. Several studies have shown that such 
technique is highly accurate and also precise in animals12,13. The 
first densitometers, such as the single photon-absorptiometry 
and the dual photon-absorptiometry (dual-energy x-ray 
absorptiometry), whose sources of energy were the gadolinium, 
have already shown superiority in relation to conventional x-rays14. 
However, the development of densitometers, whose source is 
ray-X (DEXA), has supplanted the original equipments15.   
In principle, one could establish a more relevant analogy 
between femur’s proximal area and osteoporosis. However, it 
was shown a conflicting result regarding the characteristics of 
bone loss. Bagi et al.16 observed a cortical thinning in this area, 
as it presents smaller periosteal formation but larger subendosteal 
resorption, whereas Shinoda et al.9 have not obtained the same 
results. Another criticism made, is the fact that this is a rather 
narrow region, thus hindering its interpretation. It was chosen 
not to carry out the analysis of isolated vertebras, because they 
are very small areas.  
The variation coefficient (VC), index used to measure 
the precision of the densitometric technique, revealed results 
similar to those obtained by other researchers. However, there is 
a great variation of this index (0.8% to 6.4%), which the authors 
attribute to factors such as type of decubitus used to study the 
animal, whether the analysis of the bone segment is made in vivo 
or in vitro. Besides, there are other differences regarding the 
use of one or more observers17. Studies with dissected bone in 
vitro show lower values compared to the ones obtained in vivo. 
Such fact is, probably, due to the interference of the soft tissues, 
difficulty in delimitating the areas of interest, mainly in the femur 
region, where there is the interference of interlinked bones, such 
as tibia and hip. Such facts do not exist when the bones are 
analyzed in vitro. However, the analysis in vitro does not allow 
longitudinal studies, impairing, for instance, the evaluation of the 
drug response. Nevertheless, the study in vivo makes its analysis 
more significant, thus making the study more dynamic.  
In the control group one observed in all studied phases 
a bone mineral density increase, probably related to the fact that 
animals were still growing and to weight increase with proteinous 
diet. Whether in the group of oophorectomized animals as in 
the ones submitted to aproteinous diet, bone mineral density 
decrease on the area of cortical bone (medial femur) was seen, 
thus achieving one of our purposes since oophorectomy and 
aproteinous diet take to bone loss. 
Various studies were performed showing bone loss; 
on metaphysary regions in some important works; in others on 
lumbar spine what makes evident a specific differen of each bone 
segment18. In the oophorectomized rats group, medicated with 
zoledronate, it was observed meaningful increase of bone mineral 
density in all studied phases. At the end of the study, zoledronate 
caused a bone mass increase when compared with pamidronate. 
At the end of the study histomorphometric data analyzed did not 
differ among groups, demonstrating that the medicated groups 
results were the same of the control group. 
We could obtain, thus, significant correlations among 
densitometric, biochemical and histomorphometric parameters. 
This fact is important for its practical implications. 
Conclusions
The pamidronate and zoledronate have shown effectives 
in the increment of BMD. The proteinous diet itself possesses 
therapeutic effect in BMD though not significant compared 
with medicated animals. The results of histomorphometry allow 
validating BMD’s indexes in this experimental model.
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